The changes of cytokines level in aqueous humor of patients with neovascular age-related macular degeneration following intravitreal brolucizumab.
Active, not recruiting
- Conditions
- Age-related macular degenerationBrolucizumab
- Registration Number
- TCTR20220511001
- Lead Sponsor
- Ratchadapiseksompotch Research Fund
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
1. Patients with neovascular age-related macular degeneration (nAMD) diagnosed by fundus fluorescein angiography (FFA) and/or optical coherence tomography (OCT).
2. Patients receiving intravitreal brolucizumab injection
Exclusion Criteria
1. Patients with other retinal diseases
2. History of or active ocular inflammation or infection in either eye
3. History of or active systemic autoimmune diseases or cancer
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in cytokine levels 4 weeks after first injection Milliplex Multiplex immunoassays
- Secondary Outcome Measures
Name Time Method Subretinal fluid 4 and 12 weeks after first injection OCT images,Intraocular inflammation 4 and 12 weeks after first injection Physical examination